Q2 EPS Forecast for scPharmaceuticals Lowered by Analyst

scPharmaceuticals Inc. (NASDAQ:SCPH) – Analysts at Leerink Partnrs lowered their Q2 2025 EPS estimates for shares of scPharmaceuticals in a report released on Wednesday, May 14th. Leerink Partnrs analyst R. Ruiz now expects that the company will earn ($0.37) per share for the quarter, down from their previous estimate of ($0.31). The consensus estimate for scPharmaceuticals’ current full-year earnings is ($1.53) per share. Leerink Partnrs also issued estimates for scPharmaceuticals’ Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($0.70) EPS.

Several other analysts have also weighed in on the company. Maxim Group decreased their price target on scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, March 20th. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of scPharmaceuticals in a research report on Thursday, March 20th.

scPharmaceuticals Price Performance

Shares of scPharmaceuticals stock opened at $3.29 on Monday. The stock has a market cap of $173.69 million, a price-to-earnings ratio of -1.73 and a beta of 0.17. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08. The stock has a 50 day moving average price of $2.62 and a 200-day moving average price of $3.15. scPharmaceuticals has a one year low of $1.94 and a one year high of $5.65.

scPharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.06). scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. The company had revenue of $11.75 million for the quarter, compared to the consensus estimate of $11.63 million.

Institutional Trading of scPharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Velan Capital Investment Management LP bought a new position in shares of scPharmaceuticals during the first quarter valued at approximately $2,413,000. King Luther Capital Management Corp lifted its stake in shares of scPharmaceuticals by 28.4% during the 4th quarter. King Luther Capital Management Corp now owns 2,857,910 shares of the company’s stock worth $10,117,000 after acquiring an additional 632,120 shares during the last quarter. Rice Hall James & Associates LLC boosted its holdings in scPharmaceuticals by 41.3% during the 1st quarter. Rice Hall James & Associates LLC now owns 1,398,057 shares of the company’s stock valued at $3,677,000 after acquiring an additional 408,422 shares during the period. Nantahala Capital Management LLC grew its position in scPharmaceuticals by 33.3% in the 4th quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company’s stock valued at $3,540,000 after acquiring an additional 250,000 shares during the last quarter. Finally, Apis Capital Advisors LLC grew its position in scPharmaceuticals by 146.3% in the 4th quarter. Apis Capital Advisors LLC now owns 394,000 shares of the company’s stock valued at $1,395,000 after acquiring an additional 234,000 shares during the last quarter. Institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.